SOURCE: AlphaRx Inc.

September 12, 2006 08:00 ET

AlphaRx Receives Notice of Allowance From the US Patent Office

MARKHAM, ON -- (MARKET WIRE) -- September 12, 2006 -- AlphaRx Inc. (OTCBB: ALRX), an emerging biopharmaceutical company utilizing proprietary drug delivery technology to develop novel formulations of drugs, has received a Notice of Allowance from the United States Patent and Trademark Office for its patent application entitled "Stabilization of Benzoyl Peroxide in Solution."

Benzoyl peroxide ("BP") is one of the most widely used compounds for acne treatment due to its significant antimicrobial activity, mild keratolytic and duct opening properties. The actions include a topical antimicrobial effect against infecting bacteria, the removal of the horny layer of the epidermis, as well as the removal of thickened sebum and other debris clogging follicular pores.

Benzoyl peroxide is water insoluble and this insolubility causes local skin irritation due to contact with crystalline benzoyl peroxide. This insolubility also markedly decreases benzoyl peroxide's oxidative action. Benzoyl peroxide in solution is much more efficient than micronized BP suspensions for superficial treatment, but once dissolved, the BP in solution becomes extremely unstable.

About AlphaRx Inc.

AlphaRx is an emerging biopharmaceutical company utilizing proprietary drug delivery technology to develop novel formulations of drugs that are insoluble or poorly soluble in water or have yet to be administrable to the human body with an acceptable delivery method. The Company's product candidates address various pharmaceutical markets, including arthritis, tuberculosis, ocular infection & inflammation, hospital acquired pneumonia and sepsis.

Forward-Looking Statements:

This release contains forward-looking statements within the meaning and pursuant to the Safe Harbor provisions of the Securities Litigation Reform Act of 1995 and involve risks and uncertainties that may individually or mutually impact the matters herein described, including but not limited to product development and acceptance, manufacturing, competition, regulatory and/or other factors, which are outside the control of the Company.

This press release is available on the company's official on-line investor relations site for investor commentary, feedback and questions.

Contact Information